Thursday, September 18, 2025

Latest

Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan with an IND submission for a Phase 2b trial focused on examining the use of LSD for the treatment of generalized anxiety disorder. The FDA evidently has placed a clinical hold on the study.

The justification for the clinical hold has not yet been revealed, with the company commenting that it expects additional details from the decision within the next thirty days. A clinical hold, as described by the FDA, is “an order issued by FDA to the sponsor of an IND application to delay a proposed clinical investigation or to suspend an ongoing investigation.”

A number of justifications exist for why a clinical hold may take place, but the short of it is that the regulator is not happy with one aspect of the proposed study. While the first phase outlines five potential reasons for why a study may be placed on hold, including unreasonable risk for human subjects, unqualified investigators, insufficient information, risk of reproductive or developmental toxicity and an erroneous brochure, the second phase sees the addition of potential hold due to deficient study design to meet stated objectives. It is currently unclear what grounds the study was placed on hold for.

Further information was not provided by the company on the matter.

Mind Medicine last traded at $2.12 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Pure Silver Set Up! | Joaquin Marias – Argenta Silver Corp

Why $30,000 Gold Isn’t Crazy! | Simon Marcotte – Northern Superior

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

MindMed Declares US$17.0 Million Net Loss, US$105.7 Million Cash Balance For Q2 2022

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial...

Friday, August 12, 2022, 08:20:03 AM

MindMed Declares Q2 2021 Financials: US$193.9 Million Total Assets, US$35.6 Million Net Loss

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced Thursday night its interim...

Friday, August 13, 2021, 09:08:00 AM

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM

MindMed Adds MDMA To R&D Pipeline

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching...

Wednesday, May 27, 2020, 09:00:04 AM

Mind Medicine Sees Co-Founder Become An Activist Shareholder Demanding Changes

An activist shareholder battle might be brewing at Mind Medicine (NEO: MMED). This morning, co-founder...

Thursday, August 11, 2022, 08:41:59 AM